Related Experiment Video
Updated: Dec 6, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Sphingolipid Pathway as a Source of Vulnerability in IDH1 Glioma
Tyrone Dowdy1, Lumin Zhang1, Orieta Celiku1
1Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA.
Abstract:
In addition to providing integrity to cellular structure, the various classes of lipids participate in a multitude of functions including secondary messengers, receptor stimulation, lymphocyte trafficking, inflammation, angiogenesis, cell migration, proliferation, necrosis and apoptosis, thus highlighting the importance of understanding their role in the tumor phenotype. In the context of IDH1 glioma, investigations focused on metabolic alterations involving lipidomics' present potential to uncover novel vulnerabilities. Herein, a detailed lipidomic analysis of the sphingolipid metabolism was conducted in patient-derived IDH1 glioma cell lines, as well as model systems, with the of identifying points of metabolic vulnerability. We probed the effect of decreasing D-2HG levels on the sphingolipid pathway, by treating these cell lines with an IDH1 inhibitor, AGI5198. The results revealed that N,N-dimethylsphingosine (NDMS), sphingosine C17 and sphinganine C18 were significantly downregulated, while sphingosine-1-phosphate (S1P) was significantly upregulated in glioma cultures following suppression of IDH1 activity. We exploited the pathway using a small-scale, rational drug screen and identified a combination that was lethal to IDH cells. Our work revealed that further addition of N,N-dimethylsphingosine in combination with sphingosine C17 triggered a dose-dependent biostatic and apoptotic response in a panel of IDH1 glioma cell lines specifically, while it had little effect on the IDH cells probed here. To our knowledge, this is the first study that shows how altering the sphingolipid pathway in IDH1 gliomas elucidates susceptibility that can arrest proliferation and initiate subsequent cellular death.
Insights
Researchers investigated sphingolipid metabolism in IDH1 glioma, finding that inhibiting IDH1 altered key lipid levels. A drug combination targeting these changes proved lethal to IDH1 glioma cells, offering a novel therapeutic strategy.
Area of Science:
- Biochemistry
- Oncology
- Cell Biology
Background:
- Lipids play crucial roles in cellular structure and function, including cell signaling and proliferation.
- Understanding lipid metabolism is vital for identifying cancer vulnerabilities, particularly in IDH1-mutant gliomas.
Purpose of the Study:
- To conduct a detailed lipidomic analysis of sphingolipid metabolism in IDH1-mutant glioma.
- To identify metabolic vulnerabilities within the sphingolipid pathway by targeting IDH1 activity.
- To discover therapeutic strategies by exploiting identified pathway alterations.
Main Methods:
- Performed detailed lipidomic analysis on patient-derived IDH1-mutant glioma cell lines and model systems.
- Treated cell lines with an IDH1 inhibitor (AGI5198) to decrease D-2HG levels and observe sphingolipid pathway effects.
- Conducted a rational drug screen to identify effective combinations targeting the altered sphingolipid pathway.
Main Results:
- IDH1 inhibition led to significant downregulation of N,N-dimethylsphingosine (NDMS), sphingosine C17, and sphinganine C18.
- Sphingosine-1-phosphate (S1P) was significantly upregulated in IDH1-mutant glioma cells after IDH1 activity suppression.
- A combination of NDMS and sphingosine C17 induced dose-dependent biostatic and apoptotic responses specifically in IDH1-mutant glioma cells.
Conclusions:
- Altering the sphingolipid pathway in IDH1-mutant gliomas creates specific cellular susceptibilities.
- The identified drug combination targeting sphingolipid metabolism effectively arrests proliferation and induces cell death in IDH1-mutant gliomas.
- This study presents a novel approach to targeting IDH1-mutant gliomas by exploiting metabolic vulnerabilities in sphingolipid metabolism.
Related Concept Videos
IP3/DAG Signaling Pathway
iPS Cell Differentiation
PI3K/mTOR/AKT Signaling Pathway
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Hedgehog Signaling Pathway
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...

